RYK and type 2 diabetes mellitus: Anaplastic lymphoma kinase (ALK) and Receptor-Like Tyrosine Kinase (RYK), two non-canonical receptor tyrosine kinases (RTKs), have been shown to target miR-1271 in post-mortem AD and Type 2 diabetes tissues.